FR2043504A1 - - Google Patents

Info

Publication number
FR2043504A1
FR2043504A1 FR7015663A FR7015663A FR2043504A1 FR 2043504 A1 FR2043504 A1 FR 2043504A1 FR 7015663 A FR7015663 A FR 7015663A FR 7015663 A FR7015663 A FR 7015663A FR 2043504 A1 FR2043504 A1 FR 2043504A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7015663A
Other languages
French (fr)
Other versions
FR2043504B1 (enExample
Inventor
R E Rodway
R G Simmonds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspro Nicholas Ltd
Original Assignee
Aspro Nicholas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aspro Nicholas Ltd filed Critical Aspro Nicholas Ltd
Publication of FR2043504A1 publication Critical patent/FR2043504A1/fr
Application granted granted Critical
Publication of FR2043504B1 publication Critical patent/FR2043504B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7015663A 1969-05-03 1970-04-29 Expired FR2043504B1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB22679/69A GB1293565A (en) 1969-05-03 1969-05-03 Aminophthalazines and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
FR2043504A1 true FR2043504A1 (enExample) 1971-02-19
FR2043504B1 FR2043504B1 (enExample) 1974-10-11

Family

ID=10183355

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7015663A Expired FR2043504B1 (enExample) 1969-05-03 1970-04-29

Country Status (9)

Country Link
US (1) US3753988A (enExample)
JP (1) JPS4839944B1 (enExample)
BE (1) BE749824A (enExample)
CH (1) CH523890A (enExample)
DE (1) DE2021195A1 (enExample)
FR (1) FR2043504B1 (enExample)
GB (1) GB1293565A (enExample)
IE (1) IE33777B1 (enExample)
SE (1) SE376916B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2407927A1 (fr) * 1977-11-03 1979-06-01 Pfizer Nouveaux derives de phtalazine, leur procede de production, et composition pharmaceutique les contenant
WO2004099177A1 (en) * 2003-05-09 2004-11-18 Merck Sharp & Dohme Limited Substituted-1-phthalazinamines as vr-1 antagonists

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (enExample) 1977-06-03 1981-03-07 Pfizer
US4370328A (en) 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
DE3575135D1 (de) * 1984-09-14 1990-02-08 Asta Pharma Ag Substituierte benzylphthalazinon-derivate.
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
US5106973A (en) * 1987-11-23 1992-04-21 Janssen Pharmaceutica N.V. Pyridzainamine derivatives
US4963676A (en) * 1988-02-09 1990-10-16 Georgia State University Foundation, Inc. Di-substituted phthalazines
JO1645B1 (en) * 1989-12-26 1991-11-27 شركة جانسين فارماسوتيكا ان. في Pyridazine compounds are antibacterial viruses
DE69105572T2 (de) * 1990-03-30 1995-05-11 Mitsubishi Chem Ind 4-Phenylphthalazin-Derivate.
US5100893A (en) * 1990-04-18 1992-03-31 Janssen Pharmaceutica N.V. Antipicornaviral pyridazinamines
TW279162B (enExample) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US5716956A (en) * 1995-06-07 1998-02-10 Bearsden Bearsden Bio, Inc. Dihydrophthalazine antagonists of excitatory amino acid receptors
ATE236134T1 (de) * 1996-12-18 2003-04-15 Neurogen Corp Isoquinolinamin und phtalazinamin derivate, die reagieren mit crf rezeptoren
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
US7977333B2 (en) * 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AR028782A1 (es) * 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US6903101B1 (en) 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
ES2551027T3 (es) * 2003-11-20 2015-11-13 Janssen Pharmaceutica Nv 2-Quinolinonas 7-fenilalquil sustituidas y 2-quinoxalinonas como inhibidores de poli(ADP-ribosa) polimerasa
SG151249A1 (en) * 2003-12-05 2009-04-30 Janssen Pharmaceutica Nv 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
US8338591B2 (en) 2004-05-08 2012-12-25 Novartis International Pharmaceutical Ltd. 3-aryl-5,6-disubstituted pyridazines
JP4446047B2 (ja) * 2004-06-02 2010-04-07 ケイティー コーポレーション アプリケーション及び管理サービスの提供、並びに使用者インターフェースの変更システム及びその方法
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
KR101286969B1 (ko) * 2004-06-30 2013-07-23 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 퀴나졸리논 유도체
ES2563954T3 (es) * 2004-06-30 2016-03-16 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de PARP
EP1778267A4 (en) * 2004-07-16 2010-01-06 Nitromed Inc COMPOSITIONS AND METHODS RELATED TO HEART ERROR
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP2522365B1 (en) 2004-11-24 2016-10-26 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
CA2635439A1 (en) * 2006-01-27 2007-08-02 Pfizer Products Inc. Aminophthalazine derivative compounds
WO2007097951A2 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
WO2007136626A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
KR20090040259A (ko) * 2006-05-29 2009-04-23 하이 포인트 파마슈티칼스, 엘엘씨 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 ｈ3 수용체 안타고니스트로서의 용도
SI2134691T1 (sl) * 2007-03-08 2012-06-29 Janssen Pharmaceutica Nv Derivati kvinolina kot PARP in TANK inhibitorji
JP5550352B2 (ja) 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
PL2215075T3 (pl) * 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
AU2009228945B2 (en) * 2008-03-27 2013-05-02 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
RU2490260C2 (ru) 2008-03-27 2013-08-20 Янссен Фармацевтика Нв Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
EA201071248A1 (ru) * 2008-04-29 2011-06-30 Эли Лилли Энд Компани Дизамещенные фталазиновые антагонисты пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
NZ591945A (en) * 2008-11-03 2012-10-26 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
AU2009314288B2 (en) * 2008-11-17 2013-05-02 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
BRPI0921782A2 (pt) 2008-11-17 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
US20180093956A1 (en) * 2015-02-06 2018-04-05 Abbvie Inc. Substituted phthalazines
KR102507847B1 (ko) * 2016-10-28 2023-03-08 서울대학교병원 페닐 프탈라진 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN117355303A (zh) * 2021-01-28 2024-01-05 佛罗里达大学研究基金会公司 化合物及其用于治疗神经退行性、退行性和代谢病症的用途
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US20240294542A1 (en) * 2021-06-05 2024-09-05 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and application thereof
AU2022355409B2 (en) * 2021-09-30 2025-10-16 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2407927A1 (fr) * 1977-11-03 1979-06-01 Pfizer Nouveaux derives de phtalazine, leur procede de production, et composition pharmaceutique les contenant
WO2004099177A1 (en) * 2003-05-09 2004-11-18 Merck Sharp & Dohme Limited Substituted-1-phthalazinamines as vr-1 antagonists
US7329659B2 (en) 2003-05-09 2008-02-12 Merck Sharp & Dohme Limited Substituted-1-phthalazinamines as vr-1 antagonists

Also Published As

Publication number Publication date
SE376916B (enExample) 1975-06-16
CH523890A (fr) 1972-06-15
DE2021195A1 (de) 1970-11-12
BE749824A (fr) 1970-10-30
IE33777L (en) 1970-11-03
FR2043504B1 (enExample) 1974-10-11
JPS4839944B1 (enExample) 1973-11-28
IE33777B1 (en) 1974-10-30
GB1293565A (en) 1972-10-18
US3753988A (en) 1973-08-21

Similar Documents

Publication Publication Date Title
FR2043504B1 (enExample)
AU4221168A (enExample)
AU5461069A (enExample)
AU442375B2 (enExample)
AU2355770A (enExample)
CS150600B2 (enExample)
AU427401B2 (enExample)
CS152477B2 (enExample)
AU442463B2 (enExample)
AU442380B2 (enExample)
AU442322B2 (enExample)
AU438128B2 (enExample)
AU442357B2 (enExample)
AU442554B2 (enExample)
AU428074B2 (enExample)
AU442285B2 (enExample)
AU428131B2 (enExample)
AU410358B2 (enExample)
AU425297B2 (enExample)
AU442535B2 (enExample)
AU414607B2 (enExample)
AU417208B2 (enExample)
CS149291B1 (enExample)
AU5228269A (enExample)
CS149753B1 (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse